Sun Pharma Sun Pharmaceutical has received a tentative approval to market Alfuzosin Hydrochloride Tablet in the strength of 10 mg from the United States Food and Drug Administration (USFDA).

This medicine is an alpha-blocker used in men to treat benign prostatic hyperplasia (bph).

The company is into specialty pharmaceuticals and active pharmaceutical ingredients. It operates in select therapeutic segments like psychiatry, neurology, cardiology and gastroenterology.

Shares of the company closed down Rs 2.85, or 0.22%, at Rs 1,285.75. The total volume of shares traded at the BSE was 8,796.